TY  - JOUR
A1  - Saußele, Susanne
A1  - Haverkamp, Wilhelm
A1  - Lang, Fabian
A1  - Koschmieder, Steffen
A1  - Kiani, Alexander
A1  - Jentsch-Ullrich, Kathleen
A1  - Stegelmann, Frank
A1  - Pfeifer, Heike
A1  - La Rosée, Paul
A1  - Gökbuget, Nicola
A1  - Rieger, Christina
A1  - Waller, Cornelius
A1  - Franke, Georg-Nikolaus
A1  - Le Coutre, Philipp
A1  - Kirchmair, Rudolf
A1  - Junghanß, Christian
T1  - Ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute leukemia: recommendations of a German expert consensus panel with focus on cardiovascular management
T2  - Acta haematologica
N2  - Treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute leukemia (Ph+ ALL) has been revolutionized with the advent of tyrosine kinase inhibitors (TKIs). Most patients with CML achieve long-term survival similar to individuals without CML due to treatment with TKIs not only in frontline but also in further lines of therapy. The third-generation TKI ponatinib has demonstrated efficacy in patients with refractory CML and Ph+ ALL. Ponatinib is currently the most potent TKI in this setting demonstrating activity against T315I mutant clones. However, ponatinib’s safety data revealed a dose-dependent, increased risk of serious cardiovascular (CV) events. Guidance is needed to evaluate the benefit–risk profile of TKIs, such as ponatinib, and safety measures to prevent treatment-associated CV events. An expert panel of German hematologists and cardiologists summarize current evidence regarding ponatinib’s efficacy and CV safety profile. We propose CV management strategies for patients who are candidates for ponatinib.
KW  - chronic myeloid leukemia
KW  - Philadelphia chromosome-positive acute leukemia
KW  - tyrosine kinase inhibitor
KW  - Ponatinib
KW  - cardiovascular management
KW  - consensus paper
Y1  - 2019
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/62406
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-624068
SN  - 1421-9662
VL  - 143
IS  - 3
SP  - 217
EP  - 231
PB  - Karger
CY  - Basel
ER  -